The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial



Status:Terminated
Conditions:Hospital, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases, Other
Healthy:No
Age Range:16 - 85
Updated:4/21/2016
Start Date:June 2009
End Date:September 2012

Use our guide to learn which trials are right for you!

The Oscillation for ARDS Treated Early (OSCILLATE) Trial

What is the effect of early high frequency oscillation (HFO) versus a lung-protective
conventional ventilation (CV) strategy (using HFO only as rescue therapy), on all-cause
hospital mortality among patients with severe early acute respiratory distress syndrome
(ARDS)?

High frequency oscillation is theoretically ideal for lung protection. Based on a strong
physiological rationale, rapidly expanding use internationally, and promising results in
early small RCTS, a definitive RCT to establish the impact of HFO versus current
conventional ventilation on mortality is needed. We have completed a pilot multicentre RCT
in preparation for this trial, with goals of investigating patient recruitment, protocol
acceptance, and crossover rates. The pilot study met all objectives including recruitment
that exceeded expectations (94 patients), and very good adherence to protocol. Results of
the multinational OSCILLATE Trial will establish the impact of HFO versus conventional
ventilation on mortality rates among adults with severe ARDS.

Inclusion Criteria:

- Acute onset of respiratory failure, with fewer than 2 weeks of new pulmonary
symptoms;

- Endotracheal intubation or tracheostomy;

- Hypoxaemia - defined as a partial pressure of oxygen in arterial blood
(PaO2)/fraction of inspired oxygen (FiO2) less than or equal to 200mmHg on FiO2
greater than or equal to 0.5, regardless of positive end expiratory pressure (PEEP)

- Bilateral alveolar consolidation (airspace disease) seen on frontal chest radiograph

In addition, to qualify for randomization, patients are assessed on the following
ventilator settings:

- Mode: pressure control or volume control or pressure support

- FiO2 greater than 0.6 (or higher if necessary to keep pulse oximetric saturation
[SpO2] greater than 90%)

- PEEP greater than 10 cm H2O (or greater if necessary to keep SpO2 greater than 90%)

- Tidal volume 6 ml/kg predicted body weight (PBW)

After at least 30 minutes on these settings, we sample arterial blood to assess
oxygenation. If PaO2 is less than or equal to 200 mmHg, the patient qualifies for
randomization; if PaO2/FiO2 greater than 200 mmHg, standardized hypoxaemia assessments are
repeated at least once daily for the following 72 hours (providing eligibility criteria
are still met).

Exclusion Criteria:

- Remaining duration of mechanical ventilation less than 48 hours, as judged by the
attending physician

- Primary cause of acute respiratory failure judged by attending physician to be
circulatory overload due to, for example, congestive heart failure,
hyper-resuscitation, or need for dialysis

- Suspected pulmonary haemorrhage syndrome

- Lack of commitment to ongoing life support (note that this does not include the
presence of a "Do Not Resuscitate" order alone, if there is a commitment to ongoing
life support

- Aged less than 16 years or greater than 85 years

- Weight less than 35 kg

- Severe chronic respiratory disease, as indicated by any of:

- Baseline forced expiratory volume in one second (FEV1) less than 20 ml/kg predicted
body weight

- Pre-existing chronic interstitial lung disease with chronic interstitial infiltration
on chest x-ray

- Documented chronic carbon dioxide (CO2) retention (partial pressure of carbon dioxide
in arterial blood [PaCO2] less than 50 mmHg) and/or chronic hypoxaemia(PaO2 less than
55 mmHg on FiO2=0.21)

- Chronic restrictive, obstructive, neuromuscular, chest wall or pulmonary vascular
disease resulting in severe exercise restriction (e.g., unable to climb stairs or
perform household duties), secondary polycythaemia, severe pulmonary hypertension
(mean pulmonary arterial pressure [PAP] greater than 40 mmHg), or ventilator
dependency

- Morbid obesity - defined as greater than 1 kg/cm body height

- Underlying pre-existing condition with expected 6-month mortality greater than 50%

- Neurological conditions with risk of intracranial hypertension (where hypercapnia
should be avoided)

- Neuromuscular disease that will result in prolonged need for mechanical ventilation,
including (but not limited to):

- Guillain Barre syndrome

- Cervical spinal cord injury

- Previous randomization in this trial

- All inclusion criteria present for greater than 73 hours in study intensive care unit
(ICU)

- On HFO at the time of screening
We found this trial at
9
sites
Orlando, Florida 32806
?
mi
from
Orlando, FL
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Calgary,
Click here to add this to my saved trials
5201 Harry Hines Blvd
Dallas, Texas 75235
(214) 590-8000
Parkland Memorial Hospital As our community's public health system, Parkland is the foundation for a...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denver, Colorado 80204
?
mi
from
Denver, CO
Click here to add this to my saved trials
Greenville, North Carolina 27834
?
mi
from
Greenville, NC
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Temple, TX
Click here to add this to my saved trials